KLF6
Overview
KLF6 (Kruppel-Like Factor 6) is a zinc-finger transcription factor with tumor-suppressive activity implicated in a number of solid tumors. It regulates genes involved in cell growth, differentiation, and apoptosis. In cancer genomics, KLF6 is recurrently mutated in a subset of renal cell carcinomas and other solid tumors, though it is not among the most frequently altered drivers in any single tumor type.
Alterations observed in the corpus
- Mutated in ~5% of unclassified renal cell carcinoma (uRCC, n=62 MSKCC cohort) alongside other recurrent mutations such as ATRX (7%), DNMT3A (5%), SMARCB1 (5%), NOTCH2 (5%), TP53 (5%), PBRM1 (3%), CHEK2 (3%), and BRCA2; classified as an additional recurrent mutation outside the four main uRCC molecular subsets. PMID:27713405
Cancer types (linked)
- URCC: Observed in ~5% of high-grade unclassified RCC in an MSKCC cohort (n=62); mutations cluster outside the four major molecular subsets (NF2-loss, mTORC1-hyperactive, FH-deficient, ALK-translocation). PMID:27713405
Co-occurrence and mutual exclusivity
- No specific co-occurrence or mutual exclusivity patterns reported for KLF6 in the corpus.
Therapeutic relevance
- No direct therapeutic implication reported for KLF6 in the corpus. The uRCC study identifies subset-specific therapy targets (e.g., mTOR inhibitors for mTORC1-hyperactive, YAP inhibitors for NF2-loss) but KLF6-mutated cases fall outside these defined subsets. PMID:27713405
Open questions
- Whether KLF6 mutations in uRCC are drivers or passengers remains unresolved; functional validation is not presented in the citing study.
Sources
This page was processed by crosslinker on 2026-05-14.